Jiamsakul Awachana, Kumarasamy Nagalingeswaran, Ditangco Rossana, Li Patrick C K, Phanuphak Praphan, Sirisanthana Thira, Sungkanuparph Somnuek, Kantipong Pacharee, K C Lee Christopher, Mustafa Mahiran, Merati Tuti, Kamarulzaman Adeeba, Singtoroj Thida, Law Matthew
The Kirby Institute, UNSW Australia, Sydney, Australia;
YRGCARE Medical Centre, Chennai, India.
J Int AIDS Soc. 2014 May 16;17(1):18911. doi: 10.7448/IAS.17.1.18911. eCollection 2014.
Adherence to antiretroviral therapy (ART) plays an important role in treatment outcomes. It is crucial to identify factors influencing adherence in order to optimize treatment responses. The aim of this study was to assess the rates of, and factors associated with, suboptimal adherence (SubAdh) in the first 24 months of ART in an Asian HIV cohort.
As part of a prospective resistance monitoring study, the TREAT Asia Studies to Evaluate Resistance Monitoring Study (TASER-M) collected patients' adherence based on the World Health Organization-validated Adherence Visual Analogue Scale. SubAdh was defined in two ways: (i) <100% and (ii) <95%. Follow-up time started from ART initiation and was censored at 24 months, loss to follow-up, death, treatment switch, or treatment cessation for >14 days. Time was divided into four intervals: 0-6, 6-12, 12-18 and 18-24 months. Factors associated with SubAdh were analysed using generalized estimating equations.
Out of 1316 patients, 32% ever reported <100% adherence and 17% ever reported <95%. Defining the outcome as SubAdh <100%, the rates of SubAdh for the four time intervals were 26%, 17%, 12% and 10%. Sites with an average of >2 assessments per patient per year had an odds ratio (OR)=0.7 (95% confidence interval (CI) (0.55 to 0.90), p=0.006), compared to sites with ≤2 assessments per patient per year. Compared to heterosexual exposure, SubAdh was higher in injecting drug users (IDUs) (OR=1.92, 95% CI (1.23 to 3.00), p=0.004) and lower in homosexual exposure (OR=0.52, 95% CI (0.38 to 0.71), p<0.001). Patients taking a nucleoside transcriptase inhibitor and protease inhibitor (NRTI+PI) combination were less likely to report adherence <100% (OR=0.36, 95% CI (0.20 to 0.67), p=0.001) compared to patients taking an NRTI and non-nucleoside transcriptase inhibitor (NRTI+NNRTI) combination. SubAdh decreased with increasing time on ART (all p<0.001). Similar associations were found with adherence <95% as the outcome.
We found that SubAdh, defined as either <100% and <95%, was associated with mode of HIV exposure, ART regimen, time on ART and frequency of adherence measurement. The more frequently sites assessed patients, the lower the SubAdh, possibly reflecting site resourcing for patient counselling. Although social desirability bias could not be excluded, a greater emphasis on more frequent adherence counselling immediately following ART initiation and through the first six months may be valuable in promoting treatment and programme retention.
坚持抗逆转录病毒治疗(ART)对治疗效果起着重要作用。识别影响坚持治疗的因素对于优化治疗反应至关重要。本研究的目的是评估亚洲HIV队列中ART治疗前24个月内次优依从性(SubAdh)的发生率及相关因素。
作为一项前瞻性耐药监测研究的一部分,亚洲治疗与评估耐药监测研究(TASER-M)根据世界卫生组织验证的依从性视觉模拟量表收集患者的依从性数据。SubAdh有两种定义方式:(i)<100%和(ii)<95%。随访时间从ART开始时算起,在24个月、失访、死亡、治疗转换或治疗中断超过14天时进行截尾。时间分为四个区间:0 - 6个月、6 - 12个月、12 - 18个月和18 - 24个月。使用广义估计方程分析与SubAdh相关的因素。
在1316名患者中,32%曾报告依从性<100%,17%曾报告依从性<95%。将结局定义为SubAdh<100%时,四个时间区间的SubAdh发生率分别为26%、17%、12%和10%。与每年每位患者评估次数≤2次的地点相比,每年每位患者平均评估次数>2次的地点的比值比(OR)=0.7(95%置信区间(CI)(0.55至0.90),p = 0.006)。与异性传播感染相比,注射吸毒者(IDU)的SubAdh更高(OR = 1.92,95% CI(1.23至3.00),p = 0.004),而同性传播感染的SubAdh更低(OR = 0.52,95% CI(0.38至0.71),p<0.001)。与服用核苷类逆转录酶抑制剂和非核苷类逆转录酶抑制剂(NRTI + NNRTI)组合的患者相比,服用核苷类逆转录酶抑制剂和蛋白酶抑制剂(NRTI + PI)组合的患者报告依从性<100%的可能性较小(OR = 0.36,95% CI(0.20至0.67),p = 0.001)。SubAdh随着ART治疗时间的延长而降低(所有p<0.001)。以依从性<95%作为结局时也发现了类似的关联。
我们发现,定义为<100%和<95%的SubAdh与HIV暴露方式、ART方案、ART治疗时间和依从性测量频率有关。地点对患者评估越频繁,SubAdh越低,这可能反映了为患者咨询提供的地点资源。尽管不能排除社会期望偏差,但在ART开始后立即以及前六个月更加强调更频繁的依从性咨询可能对促进治疗和项目留存有价值。